Treatment News : Genetically Engineered Antibodies Protect Mice From HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 18, 2014

Genetically Engineered Antibodies Protect Mice From HIV

Engineering immune cells to produce “broadly neutralizing antibodies” (BNAs) protects mice that have immune systems modified to resemble those of humans against HIV infection. Researchers funded by the National Institutes of Health and working in the laboratory of Nobel laureate David Baltimore, PhD, at the California Institute of Technology published their findings in Nature Medicine.

BNAs prevent infection by blocking the receptors HIV uses to latch onto human cells. About one in five people produce them as a response to HIV, but usually do so too late to thwart a chronic infection; scientists are seeking ways to prompt the development of BNAs before HIV exposure.

The researchers in this study spliced genes for  HIV-specific BNA called VRC01 into what’s known as a vector, which is a virus that is not harmful but can deliver the genetic coding into immune cells. Then they infected mice with the vector, prompting particular cells to produce the BNAs over extended periods of time.

The investigators sought to replicate human sexual transmission of HIV by repeatedly exposing the mice to low doses of HIV. In one experiment, two out of 10 mice that received the VRC01 vector became infected with the laboratory strain of the virus following 13 to 15 exposures. Meanwhile, all of the nine mice that did not receive the BNA-inducing vector were infected within just six exposures to the virus. In a second experiment, the researchers used a modified version of VRC01 as their vector, called VRC07, and exposed the mice to an HIV strain that is common in humans. The mice that received the VRC07 vector were totally resistant to HIV.

To read the NIH press release on the study, click here.

To read the study abstract, click here.

Search: Genetic therapy, broadly neutralizing antibodies, BNAs, National Institutes of Health, David Baltimore, California Institute of Technology, Nature Medicine, VRC01, VRC07, mice, HIV.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.